Novo Nordisk lowers self-pay prices for weight loss drugs ahead of Lilly, TrumpRxnews2025-11-17T18:22:42+00:00November 17th, 2025|Endpoints News|
Scholar Rock plans to launch spinal muscular atrophy drug next yearnews2025-11-17T17:48:23+00:00November 17th, 2025|Endpoints News|
Merck is still hunting for deals after two major bolt-on acquisitions this yearnews2025-11-17T15:58:32+00:00November 17th, 2025|Endpoints News|
J&J to buy Halda for $3.05B, adding startup’s RIPTAC cancer drugnews2025-11-17T14:27:30+00:00November 17th, 2025|Endpoints News|
Nuvalent shares Phase 1/2 data for ALK inhibitor that could battle with Pfizer’s Lorbrenanews2025-11-17T11:50:47+00:00November 17th, 2025|Endpoints News|
Lilly makes up to $2.6B pact with South Korean biotech ABL Bionews2025-11-17T10:28:16+00:00November 17th, 2025|Endpoints News|
Genmab cans another ADC from ProfoundBio deal in area of J&J’s Ambrx buyoutnews2025-11-17T10:04:19+00:00November 17th, 2025|Endpoints News|
CHMP endorses Sanofi diabetes drug, Lilly breast cancer treatmentnews2025-11-14T19:42:51+00:00November 14th, 2025|Endpoints News|
Bristol Myers, J&J’s next-gen blood thinner fails key trial in another setback for factor XInews2025-11-14T16:16:30+00:00November 14th, 2025|Endpoints News|
Exclusive: The inside story of Pfizer and Novo’s fight for the $10B Metsera dealnews2025-11-14T14:00:19+00:00November 14th, 2025|Endpoints News|
